Literature DB >> 23685068

The prospects and challenges of universal vaccines for influenza.

Kanta Subbarao1, Yumiko Matsuoka.   

Abstract

Vaccination is the most effective way to reduce the impact of epidemic as well as pandemic influenza. However, the licensed inactivated influenza vaccine induces strain-specific immunity and must be updated annually. When novel viruses appear, matched vaccines are not likely to be available in time for the first wave of a pandemic. Yet, the enormous diversity of influenza A viruses in nature makes it impossible to predict which subtype or strain will cause the next pandemic. Several recent scientific advances have generated renewed enthusiasm and hope for universal vaccines that will induce broad protection from a range of influenza viruses. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23685068      PMCID: PMC3700639          DOI: 10.1016/j.tim.2013.04.003

Source DB:  PubMed          Journal:  Trends Microbiol        ISSN: 0966-842X            Impact factor:   17.079


  89 in total

1.  The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: a meta-analysis of 8 randomized controlled studies.

Authors:  Christopher S Ambrose; Xionghua Wu; Markus Knuf; Peter Wutzler
Journal:  Vaccine       Date:  2011-12-07       Impact factor: 3.641

Review 2.  Immunodominance: a pivotal principle in host response to viral infections.

Authors:  Ali Akram; Robert D Inman
Journal:  Clin Immunol       Date:  2012-02-10       Impact factor: 3.969

3.  The magnitude and specificity of influenza A virus-specific cytotoxic T-lymphocyte responses in humans is related to HLA-A and -B phenotype.

Authors:  A C M Boon; G de Mutsert; Y M F Graus; R A M Fouchier; K Sintnicolaas; A D M E Osterhaus; G F Rimmelzwaan
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

4.  Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells.

Authors:  Gui-Mei Li; Christopher Chiu; Jens Wrammert; Megan McCausland; Sarah F Andrews; Nai-Ying Zheng; Jane-Hwei Lee; Min Huang; Xinyan Qu; Srilatha Edupuganti; Mark Mulligan; Suman R Das; Jonathan W Yewdell; Aneesh K Mehta; Patrick C Wilson; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-21       Impact factor: 11.205

5.  Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults.

Authors:  Christine B Turley; Richard E Rupp; Casey Johnson; David N Taylor; Julie Wolfson; Lynda Tussey; Uma Kavita; Lawrence Stanberry; Alan Shaw
Journal:  Vaccine       Date:  2011-05-30       Impact factor: 3.641

6.  A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins.

Authors:  Davide Corti; Jarrod Voss; Steven J Gamblin; Giosiana Codoni; Annalisa Macagno; David Jarrossay; Sebastien G Vachieri; Debora Pinna; Andrea Minola; Fabrizia Vanzetta; Chiara Silacci; Blanca M Fernandez-Rodriguez; Gloria Agatic; Siro Bianchi; Isabella Giacchetto-Sasselli; Lesley Calder; Federica Sallusto; Patrick Collins; Lesley F Haire; Nigel Temperton; Johannes P M Langedijk; John J Skehel; Antonio Lanzavecchia
Journal:  Science       Date:  2011-07-28       Impact factor: 47.728

7.  Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity.

Authors:  Andrea Jegerlehner; Nicole Schmitz; Tazio Storni; Martin F Bachmann
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

8.  Universal influenza DNA vaccine encoding conserved CD4+ T cell epitopes protects against lethal viral challenge in HLA-DR transgenic mice.

Authors:  Jeff Alexander; Pamuk Bilsel; Marie-France del Guercio; Stephani Stewart; Aleksandra Marinkovic-Petrovic; Scott Southwood; Claire Crimi; Lo Vang; Les Walker; Glenn Ishioka; Vivek Chitnis; Alessandro Sette; Erika Assarsson; Drew Hannaman; Jason Botten; Mark J Newman
Journal:  Vaccine       Date:  2009-11-04       Impact factor: 3.641

9.  Generation of both cross-reactive and virus-specific T-cell populations after immunization with serologically distinct influenza A viruses.

Authors:  R B Effros; P C Doherty; W Gerhard; J Bennink
Journal:  J Exp Med       Date:  1977-03-01       Impact factor: 14.307

10.  Heterovariant cross-reactive B-cell responses induced by the 2009 pandemic influenza virus A subtype H1N1 vaccine.

Authors:  Xiao-Song He; Sanae Sasaki; Jane Baer; Surender Khurana; Hana Golding; John J Treanor; David J Topham; Mark Y Sangster; Hong Jin; Cornelia L Dekker; Kanta Subbarao; Harry B Greenberg
Journal:  J Infect Dis       Date:  2012-10-29       Impact factor: 5.226

View more
  23 in total

1.  Microneedle patch delivery to the skin of virus-like particles containing heterologous M2e extracellular domains of influenza virus induces broad heterosubtypic cross-protection.

Authors:  Min-Chul Kim; Jeong Woo Lee; Hyo-Jick Choi; Yu-Na Lee; Hye Suk Hwang; Jongsang Lee; Cheol Kim; Jong Seok Lee; Carlo Montemagno; Mark R Prausnitz; Sang-Moo Kang
Journal:  J Control Release       Date:  2015-05-21       Impact factor: 9.776

2.  High-Yield Expression of M2e Peptide of Avian Influenza Virus H5N1 in Transgenic Duckweed Plants.

Authors:  Aleksey Firsov; Irina Tarasenko; Tatiana Mitiouchkina; Natalya Ismailova; Lyubov Shaloiko; Alexander Vainstein; Sergey Dolgov
Journal:  Mol Biotechnol       Date:  2015-07       Impact factor: 2.695

3.  Hemagglutinin Stalk Immunity Reduces Influenza Virus Replication and Transmission in Ferrets.

Authors:  Raffael Nachbagauer; Matthew S Miller; Rong Hai; Alex B Ryder; John K Rose; Peter Palese; Adolfo García-Sastre; Florian Krammer; Randy A Albrecht
Journal:  J Virol       Date:  2015-12-30       Impact factor: 5.103

Review 4.  Influenza vaccines: challenges and solutions.

Authors:  Katherine Houser; Kanta Subbarao
Journal:  Cell Host Microbe       Date:  2015-03-11       Impact factor: 21.023

Review 5.  Challenges of selecting seasonal influenza vaccine strains for humans with diverse pre-exposure histories.

Authors:  Scott E Hensley
Journal:  Curr Opin Virol       Date:  2014-08-11       Impact factor: 7.090

6.  Roles of antibodies to influenza A virus hemagglutinin, neuraminidase, and M2e in conferring cross protection.

Authors:  Yu-Jin Kim; Eun-Ju Ko; Min-Chul Kim; Yu-Na Lee; Ki-Hye Kim; Yu-Jin Jung; Sang-Moo Kang
Journal:  Biochem Biophys Res Commun       Date:  2017-09-05       Impact factor: 3.575

7.  Immunologic consequences of chemotherapy for ovarian cancer: impaired responses to the influenza vaccine.

Authors:  Christina S Chu; Jean D Boyer; Abbas Jawad; Kenyetta McDonald; Wade T Rogers; Eline T Luning Prak; Kathleen E Sullivan
Journal:  Vaccine       Date:  2013-09-13       Impact factor: 3.641

8.  Immunogenicity and efficacy of replication-competent recombinant influenza virus carrying multimeric M2 extracellular domains in a chimeric hemagglutinin conjugate.

Authors:  Min-Chul Kim; Yu-Na Lee; Yu-Jin Kim; Hyo-Jick Choi; Ki-Hye Kim; Youn-Jeong Lee; Sang-Moo Kang
Journal:  Antiviral Res       Date:  2017-10-26       Impact factor: 5.970

9.  Genome-wide mutagenesis of influenza virus reveals unique plasticity of the hemagglutinin and NS1 proteins.

Authors:  Nicholas S Heaton; David Sachs; Chi-Jene Chen; Rong Hai; Peter Palese
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-25       Impact factor: 11.205

10.  Isolation of Neutralizing Human Single Chain Antibodies Against Conserved Hemagglutinin Epitopes of Influenza a Virus H3N2 Strain.

Authors:  Mahboubeh Poursiami; Setareh Moazen; Foroogh Nejatollahi; Afagh Moatari
Journal:  Rep Biochem Mol Biol       Date:  2019-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.